FGF-4 Antibody

Recombinant Human FGF‑4 (Catalog # 235-F4) stimulates proliferation in the NR6R‑3T3 mouse fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human FGF‑4 (0.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human FGF‑4 Polyclonal Antibody (Catalog # AB-235-NA). The ND50 is typically 6-9 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

FGF-4 Antibody Summary

• Immunogen: E. coli-derived recombinant human FGF-4
  Ala31-Leu206
  Accession # P08620
• Specificity: Detects human FGF-4 in direct ELISAs and Western blots. In direct ELISAs, less than 50% cross-reactivity with recombinant mouse FGF-4 is observed, and less than 15% cross-reactivity with recombinant human (rh) FGF-6 is observed. It will not neutralize the biological activity of bovine FGF acidic, rhFGF acidic, bovine FGF basic, rhFGF basic, rhFGF-5, rhFGF-6, or rh beta -ECGF.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FGF4
• Purity Statement: Protein A or G purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 6-9 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 1 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGF-4 Antibody

• FGF4
• FGF-4
• fibroblast growth factor 4
• HBGF-4
• HBGF-4Transforming protein KS3
• heparin secretory transforming protein 1
• Heparin secretory-transforming protein 1
• Heparin-binding growth factor 4
• HST-1
• HST-1HSTF-1
• HSTF1fibroblast growth factor 4 splice isoform
• HSTFGF-4
• human stomach cancer, transforming factor from FGF-related oncogene
• kaposi sarcoma oncogene
• KFGF
• K-FGF
• KS3
• oncogene HST

Background

FGF-4, the product of a developmentally regulated gene (hst-1), is a member of the FGF family that is efficiently secreted. The gene for FGF-4 (also known as FGFK or K-FGF for Kaposi sarcoma-associated FGF) was initially discovered as a transforming gene by the NIH-3T3 focus formation assay using DNA derived from human tumors (including stomach and colon cancers, hepatocellular carcinomas, and Kaposi’s sarcomas). FGF-4 does not seem to be expressed in normal adult tissues. However, expression of the gene is spatially and temporally regulated during embryonic development. The murine homologue of human FGF-4 has been cloned and shown to be 82% homologous to the human protein at the amino acid sequence level. Human FGF-4 has been shown to exhibit cross species activity. In vitro, FGF-4 is mitogenic for fibroblasts and endothelial cells. FGF-4 has been shown to be a potent angiogenesis promoter in vivo. FGF-4 has potent transforming potential apparently through an autocrine mechanism of action. FGF-4 plays a key role in limb development and has been identified as the molecular mediator of the activities of the apical ectodermal ridge that is required for directing the outgrowth and patterning of vertebrate limbs.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FGF4
• Uniprot:
  • P08620()